Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RADIANT-TB: Standard vs Double Dose Dolutegravir in HIV/TB
NCT03851588Phase 2Completed
- Sponsor
- University of Cape Town
- Start
- Dec 2019
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of dolutegravir in human immunodeficiency virus infection (HIV) (2 arms), sponsored by University of Cape Town. Primary endpoint: Virological Suppression at 24 Weeks. Started Dec 2019; status: completed.
02
Drugs
dolutegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03851588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03851588.